

Luca Boni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8242623/publications.pdf>

Version: 2024-02-01

198
papers

10,440
citations

50566

48
h-index

40945

97
g-index

203
all docs

203
docs citations

203
times ranked

13295
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 400-408.	3.0	15
2	The Marginsâ€™ Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast Cancer. <i>In Vivo</i> , 2022, 36, 814-820.	0.6	4
3	Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial. <i>European Respiratory Journal</i> , 2022, 60, 2200025.	3.1	33
4	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 876-887.	5.1	83
5	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	0.8	24
6	Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 159-166.	5.2	42
7	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	1.9	9
8	Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. <i>Clinical Cancer Research</i> , 2021, 27, 3576-3583.	3.2	10
9	Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. <i>Npj Breast Cancer</i> , 2021, 7, 34.	2.3	5
10	Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). <i>Current Oncology</i> , 2021, 28, 1761-1772.	0.9	5
11	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	2.3	6
12	The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 690320.	1.3	23
13	Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. <i>Clinical Lung Cancer</i> , 2021, 22, 473-477.	1.1	23
14	Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100214.	0.6	3
15	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1438-1447.	5.1	45
16	Efficacy and indications of dilation-assisted stone extraction for retrieval of difficult common bile duct stones: Results and data analysis of a single Italian referral center for bilio-pancreatic disease treatment. <i>Minerva Medica</i> , 2021, 112, 653-655.	0.3	0
17	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	2.2	6
18	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	1.1	53

#	ARTICLE	IF	CITATIONS
19	Congenital Muscular Mitral-Aortic Discontinuity Identified in Patients With Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2238-2247.	1.2	15
20	Study protocol: treatment with caffeine of the very preterm infant in the delivery room: a feasibility study. <i>BMJ Open</i> , 2020, 10, e040105.	0.8	4
21	DNA Fragmentation in Viable and Non-Viable Spermatozoa Discriminates Fertile and Subfertile Subjects with Similar Accuracy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1341.	1.0	5
22	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 497-507.	5.1	196
23	Reference ranges of Presepsin in preterm infants in the first 48h of life: A multicenter observational study. <i>Clinica Chimica Acta</i> , 2020, 508, 191-196.	0.5	12
24	hERG1 and HIF-2 β Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients. <i>Translational Oncology</i> , 2020, 13, 100740.	1.7	21
25	Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). <i>British Journal of Cancer</i> , 2020, 123, 26-32.	2.9	17
26	The European Academy of Andrology (EAA) ultrasound study on healthy, fertile men: clinical, seminal and biochemical characteristics. <i>Andrology</i> , 2020, 8, 1005-1020.	1.9	37
27	Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. <i>Annals of Oncology</i> , 2019, 30, 1969-1977.	0.6	27
28	Patent ductus arteriosus in preterm infants born at 23-24 weeks' gestation: Should we pay more attention?. <i>Early Human Development</i> , 2019, 135, 16-22.	0.8	21
29	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREN trial. <i>Breast Cancer Research</i> , 2019, 21, 71.	2.2	19
30	Sperm selection with density gradient centrifugation and swim up: effect on DNA fragmentation in viable spermatozoa. <i>Scientific Reports</i> , 2019, 9, 7492.	1.6	71
31	Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1629-1637.	0.8	143
32	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	1.3	25
33	TREC and KREC in very preterm infants: reference values and effects of maternal and neonatal factors. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 34, 1-6.	0.7	10
34	Effect modifiers in a randomized phase III trial of low-dose tamoxifen in breast preinvasive disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1500-1500.	0.8	3
35	Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3508-3508.	0.8	17
36	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. <i>Annals of Oncology</i> , 2018, 29, 1528-1534.	0.6	83

#	ARTICLE	IF	CITATIONS
37	Evaluation of candidemia and antifungal consumption in a large tertiary care Italian hospital over a 12-year period. <i>Infection</i> , 2018, 46, 469-476.	2.3	20
38	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	3.4	87
39	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. <i>Annals of Oncology</i> , 2018, 29, 924-930.	0.6	99
40	New perspectives on the long-term outcome of segmental colectomy for Crohn's colitis: an observational study on 200 patients. <i>International Journal of Colorectal Disease</i> , 2018, 33, 479-485.	1.0	5
41	Comparing laparoscopic surgery with open surgery for long-term outcomes in patients with stage I to III colon cancer. <i>Surgical Oncology</i> , 2018, 27, 115-122.	0.8	15
42	Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR03). <i>Oncologist</i> , 2018, 23, 912-918.	1.9	16
43	Effects of surfactant treatment in late preterm infants with respiratory distress syndrome. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2018, 31, 1259-1266.	0.7	16
44	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 1981-1990.	0.8	268
45	Is the door open to further investigation with antiangiogenesis in SCLC?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1127-S1128.	0.6	0
46	Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study. <i>Annals of Oncology</i> , 2018, 29, viii674.	0.6	0
47	Multicentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. <i>Annals of Oncology</i> , 2018, 29, viii644.	0.6	0
48	Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. <i>British Journal of Cancer</i> , 2018, 119, 1326-1331.	2.9	15
49	Placental Circulation Intact Trial (PCI-T) Resuscitation With the Placental Circulation Intact vs. Cord Milking for Very Preterm Infants: A Feasibility Study. <i>Frontiers in Pediatrics</i> , 2018, 6, 364.	0.9	29
50	CFH Y402H polymorphism in Italian patients with age-related macular degeneration, retinitis pigmentosa, and Stargardt disease. <i>Ophthalmic Genetics</i> , 2018, 39, 699-705.	0.5	5
51	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	2.0	20
52	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98.	1.1	17
53	Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-14.	0.7	16
54	Role of transanal irrigation in the treatment of anterior resection syndrome. <i>Techniques in Coloproctology</i> , 2018, 22, 519-527.	0.8	56

#	ARTICLE	IF	CITATIONS
55	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. <i>Annals of Oncology</i> , 2018, 29, 1748-1754.	0.6	76
56	Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 351-351.	0.8	2
57	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7859-7866.	0.8	25
58	Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24078-e24078.	0.8	0
59	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1281-1287.	0.8	126
60	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 318-323.	2.9	29
61	Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 922-928.	1.7	26
62	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	1.1	28
63	Psychopathology in cancer patients through highlights and inconclusive issues: outcomes of an Italian cross-sectional survey. <i>Minerva Psichiatria</i> , 2017, 58, .	0.3	0
64	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2â”) metastatic breast cancer (mBC) (TREnd trial).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1002-1002.	0.8	14
65	hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6325-6332.	1.0	18
66	FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. <i>Annals of Oncology</i> , 2016, 27, vi560.	0.6	7
67	Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction. <i>Annals of Oncology</i> , 2016, 27, 1280-1286.	0.6	5
68	Efficacy of a new technique â€“ INtubate-RECruiT-SURfactant-Extubate â€“ âœIN-REC-SUR-Eâ€•â€“ in preterm neonates with respiratory distress syndrome: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 414.	0.7	18
69	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016, 100, 30-37.	0.9	3
70	Nab-paclitaxel in substitution of oxaliplatin and irinotecan in folfirinox schedule as first-line therapy in patients with metastatic pancreatic cancer: results of phase I dose finding of NabucCO study by GOIRC. <i>Annals of Oncology</i> , 2016, 27, vi230.	0.6	0
71	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. <i>Annals of Oncology</i> , 2016, 27, vi152.	0.6	3
72	Variation of DNA Fragmentation Levels During Density Gradient Sperm Selection for Assisted Reproduction Techniques. <i>Medicine (United States)</i> , 2016, 95, e3624.	0.4	68

#	ARTICLE	IF	CITATIONS
73	Is thyroid hormones evaluation of clinical value in the work-up of males of infertile couples?. Human Reproduction, 2016, 31, 518-529.	0.4	38
74	Comparison of the transcutaneous bilirubinometers BiliCare and Minolta JM-103 in late preterm and term neonates. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 3014-3018.	0.7	14
75	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Annals of Oncology, 2016, 27, 843-849.	0.6	46
76	Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.. Journal of Clinical Oncology, 2016, 34, 3521-3521.	0.8	25
77	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in <i>RAS</i> / <i>BRAF</i> wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. Journal of Clinical Oncology, 2016, 34, 3543-3543.	0.8	9
78	Analysis of early distant metastases of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.. Journal of Clinical Oncology, 2016, 34, e15149-e15149.	0.8	1
79	hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance. Oncotarget, 2016, 7, 59535-59547.	0.8	15
80	Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.. Journal of Clinical Oncology, 2016, 34, 8513-8513.	0.8	0
81	TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2016, 34, TPS3629-TPS3629.	0.8	0
82	Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.. Journal of Clinical Oncology, 2016, 34, e15127-e15127.	0.8	0
83	B-cell lymphoma 2 and β -catenin expression in colorectal cancer and their prognostic role following surgery. Molecular Medicine Reports, 2015, 12, 553-560.	1.1	7
84	Second-line Treatment of Small Cell Lung Cancer: Is Platinum Sensitivity a Relevant Prognostic Factor?. Journal of Thoracic Oncology, 2015, 10, e35-e36.	0.5	0
85	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. Annals of Oncology, 2015, 26, vi1.	0.6	0
86	Implementation and preliminary validation of a new score that predicts postoperative complications. Acta Anaesthesiologica Scandinavica, 2015, 59, 609-618.	0.7	4
87	An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology, 2015, 3, 909-918.	1.9	32
88	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pNO Breast Cancer. PLoS ONE, 2015, 10, e0136731.	1.1	11
89	The Trend of CEACAM3 Blood Expression as Number Index of the CTCs in the Colorectal Cancer Perioperative Course. Mediators of Inflammation, 2015, 2015, 1-7.	1.4	2
90	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. JAMA - Journal of the American Medical Association, 2015, 314, 2632.	3.8	180

#	ARTICLE	IF	CITATIONS
91	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients. <i>Annals of Oncology</i> , 2015, 26, vi1.	0.6	28
92	Sustained Lung Inflation at Birth for Preterm Infants: A Randomized Clinical Trial. <i>Pediatrics</i> , 2015, 135, e457-e464.	1.0	121
93	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015, 26, 724-730.	0.6	136
94	hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2015, 112, 1076-1087.	2.9	47
95	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015, 26, 2107-2113.	0.6	85
96	Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. <i>American Journal of Surgery</i> , 2015, 210, 35-44.	0.9	40
97	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. <i>Annals of Oncology</i> , 2015, 26, 1188-1194.	0.6	153
98	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncology</i> , The, 2015, 16, 1306-1315.	5.1	835
99	Italian Multicenter Phase III Randomized Study of Cisplatin Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial. <i>Clinical Lung Cancer</i> , 2015, 16, 67-70.	1.1	17
100	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3510-3510.	0.8	8
101	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-657.	0.8	17
102	Abstract P5-18-05: The Promher Study: An observational Italian study on HER2+ve, pT1a-b, pNO, MO breast cancer (BC) patients (pts). , 2015, , .		0
103	Phase II study of pre-operative panitumumab and external pelvic radiotherapy (RT) in locally advanced rectal cancer (LARC) patients (pts) (RaP/STAR-03 Study): Preliminary report of safety and treatment compliance.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14502-e14502.	0.8	0
104	Correction: hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications. <i>Clinical Cancer Research</i> , 2014, 20, 2501-2501.	3.2	1
105	VEGF-A clinical significance in gastric cancers: Immunohistochemical analysis of a wide Italian cohort. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1291-1298.	0.5	3
106	hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications. <i>Clinical Cancer Research</i> , 2014, 20, 1502-1512.	3.2	54
107	Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan. <i>Lung Cancer</i> , 2014, 86, 91-95.	0.9	36
108	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1609-1618.	13.9	845

#	ARTICLE	IF	CITATIONS
109	Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials. <i>European Journal of Cancer</i> , 2014, 50, 2211-2218.	1.3	46
110	Risk of Sudden Death and Outcome in Patients With Hypertrophic Cardiomyopathy With Benign Presentation and Without Risk Factors. <i>American Journal of Cardiology</i> , 2014, 113, 1550-1555.	0.7	107
111	First-Line Chemotherapy Treatment of Advanced Non-Small-Cell Lung Cancer: Does Cisplatin versus Carboplatin Make a Difference?. <i>Journal of Thoracic Oncology</i> , 2014, 9, e82.	0.5	4
112	Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3519-3519.	0.8	9
113	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3596-3596.	0.8	4
114	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 105-105.	0.8	8
115	Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 521-521.	0.8	2
116	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 471-471.	0.8	8
117	Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. <i>World Journal of Gastroenterology</i> , 2014, 20, 786.	1.4	24
118	A prospective study to evaluate the Vulnerable Elders Survey-13 (VES-13) as a tool to identify frail older cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9546-9546.	0.8	0
119	Sustained lung inflation in the delivery room in preterm infants at high risk of respiratory distress syndrome (SLI STUDY): study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 67.	0.7	16
120	Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1527-1535.	1.2	240
121	Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 82, 288-293.	0.9	32
122	Sustained lung inflation to manage preterm infants (25-29 weeks' gestation) in the delivery room: the Italian SLI study. <i>Early Human Development</i> , 2013, 89, S115-S116.	0.8	0
123	ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. <i>British Journal of Cancer</i> , 2013, 108, 1695-1703.	2.9	67
124	High hERG1 expression in advanced melanoma. <i>Melanoma Research</i> , 2013, 23, 185-190.	0.6	6
125	Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?. <i>Annals of Oncology</i> , 2013, 24, 494-500.	0.6	27
126	FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. <i>Annals of Oncology</i> , 2013, 24, iv21.	0.6	5

#	ARTICLE	IF	CITATIONS
127	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCR): Results of the phase III randomized TRIBE trial.. Journal of Clinical Oncology, 2013, 31, 336-336.	0.8	25
128	The Frequency of Granulocytes with Spontaneous Somatic Mutations: A Wide Distribution in a Normal Human Population. PLoS ONE, 2013, 8, e54046.	1.1	36
129	A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. European Heart Journal, 2012, 33, 2080-2087.	1.0	88
130	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage III-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). British Journal of Cancer, 2012, 106, 658-665.	2.9	18
131	Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial. Journal of Clinical Oncology, 2012, 30, 4501-4507.	0.8	47
132	hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. Translational Oncology, 2012, 5, 105-112.	1.7	51
133	A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 369-375.	1.1	2
134	Role of the Somatic Mutation Rate in Patients with Classical Myeloproliferative Neoplasms (MPN) with and without Other Neoplasms. Blood, 2012, 120, 5055-5055.	0.6	0
135	Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial. Journal of Clinical Oncology, 2011, 29, 2773-2780.	0.8	702
136	From Clinical Trials to Clinical Practice: Predictors of Response to Erlotinib in Advanced Non-Small Cell Lung Cancer Patients Pretreated with Chemotherapy. Tumori, 2011, 97, 160-165.	0.6	10
137	Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1. Journal of Clinical Oncology, 2011, 29, 449-455.	0.8	101
138	Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 269-76.	3.8	311
139	Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.. Journal of Clinical Oncology, 2011, 29, 7555-7555.	0.8	0
140	Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Transplant Infectious Disease, 2010, 12, 505-512.	0.7	35
141	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers. Lung Cancer, 2010, 67, 355-360.	0.9	76
142	Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group.. Journal of Clinical Oncology, 2010, 28, 528-528.	0.8	13
143	Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2009, 104, 1727-1731.	0.7	93
144	Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification. Journal of Clinical Oncology, 2009, 27, 1034-1040.	0.8	134

#	ARTICLE	IF	CITATIONS
145	9136 Erlotinib as a second-line therapy in advanced non small cell lung cancer: correlation between clinical characteristics and biomarkers. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 546.	2.2	1
146	Diagnostic Accuracy of Computed Tomographic Colonography for the Detection of Advanced Neoplasia in Individuals at Increased Risk of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2453.	3.8	199
147	Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Aduvante Retto (STAR)-01 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2009, 27, CRA4008-CRA4008.	0.8	52
148	Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1104-1111.	0.5	32
149	Validating a Measure to Delineate the Clinical Trials Nursing Role in Italy. <i>Cancer Nursing</i> , 2008, 31, E11-E15.	0.7	9
150	Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2007, 99, 847-857.	3.0	574
151	A3-06: Triplets versus doublets with or without cisplatin in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: preliminary results of a multicenter randomized factorial study. <i>Journal of Thoracic Oncology</i> , 2007, 2, S318.	0.5	1
152	Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. <i>Annals of Oncology</i> , 2006, 17, 74-78.	0.6	92
153	Metabolic Treatment with L-Carnitine in Acute Anterior ST Segment Elevation Myocardial Infarction. <i>Cardiology</i> , 2006, 106, 215-223.	0.6	42
154	A Phase II Trial with Cisplatin-Paclitaxel Cytotoxic Treatment and Concurrent External and Endocavitary Radiation Therapy in Locally Advanced or Recurrent Cervical Cancer. <i>Oncology</i> , 2006, 70, 19-24.	0.9	24
155	Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group. <i>Acta Oncol³gica</i> , 2006, 45, 168-174.	0.8	18
156	Glutathione S-transferase polymorphisms and susceptibility to neuroblastoma. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 423-426.	0.7	7
157	Fate of embryonal carcinoma cells injected into postimplantation mouse embryos. <i>Differentiation</i> , 2005, 73, 484-490.	1.0	27
158	Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxis³A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 569-575.	0.8	85
159	Platinum-Based Versus Non³Platinum-Based Chemotherapy in Advanced Non³Small-Cell Lung Cancer: Does Cisplatin Versus Carboplatin Make a Difference?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6276-6277.	0.8	5
160	The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. <i>Cancer Letters</i> , 2005, 228, 257-266.	3.2	48
161	Temporary ovarian suppression with goserelin for prevention of chemotherapy-induced menopause in young early breast cancer patients: Results of a phase II study. <i>Journal of Clinical Oncology</i> , 2005, 23, 662-662.	0.8	3
162	Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 116-120.	2.0	9

#	ARTICLE	IF	CITATIONS
163	Biological and clinical role of p73 in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 111-117.	3.2	19
164	Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. <i>European Journal of Cancer</i> , 2003, 39, 1242-1250.	1.3	76
165	Effect of a palliative home care team on hospital admissions among patients with advanced cancer. <i>Palliative Medicine</i> , 2003, 17, 315-321.	1.3	74
166	Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 1592-1601.	0.8	153
167	A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 359-365.	1.1	39
168	Title is missing!. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 359-365.	1.1	36
169	Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. <i>Clinical Cancer Research</i> , 2003, 9, 2032-9.	3.2	151
170	Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. <i>Annals of Oncology</i> , 2002, 13, 956-964.	0.6	31
171	Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 25-28.	1.1	5
172	Expression of ^{125}I -Np73 is a molecular marker for adverse outcome in neuroblastoma patients. <i>Cell Death and Differentiation</i> , 2002, 9, 246-251.	5.0	183
173	Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC). <i>British Journal of Cancer</i> , 2001, 85, 1452-1455.	2.9	11
174	Natural killer cells lyse autologous herpes simplex virus infected targets using cytolytic mechanisms distributed clonotypically. <i>Journal of Medical Virology</i> , 2000, 62, 354-363.	2.5	20
175	Ambamustine in the Second-Line Treatment of Patients With Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 22-25.	0.6	7
176	Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 1999, 81, 310-315.	2.9	23
177	Stage-independent expression and genetic analysis of p73 in neuroblastoma. , 1999, 84, 365-369.		14
178	The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome. <i>American Journal of Cardiology</i> , 1998, 82, 1205-1209.	0.7	102
179	Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome. <i>Cancer Letters</i> , 1998, 130, 83-92.	3.2	19
180	Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. <i>Gastrointestinal Endoscopy</i> , 1997, 46, 124-130.	0.5	42

#	ARTICLE	IF	CITATIONS
181	MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.. Journal of Clinical Oncology, 1997, 15, 85-93.	0.8	111
182	Prognostic factors in patients with hepatocellular carcinoma submitted to chemoembolization. Oncology Reports, 1997, 4, 1025-8.	1.2	2
183	Multigeneration maternal transmission in Italian families with neural tube defects. American Journal of Medical Genetics Part A, 1996, 66, 303-310.	2.4	11
184	Prognostic value of proliferating cell nuclear antigen (PCNA) expression in unresectable hepatocellular carcinoma. International Journal of Oncology, 1996, 9, 541-5.	1.4	0
185	A Multicenter Study of Colorectal Adenomas Rationale, Objectives, Methods and Characteristics of the Study Cohort. Tumori, 1995, 81, 157-163.	0.6	8
186	PROGNOSTIC EVALUATION OF PATIENTS SUBMITTED TO SURGERY FOR MALIGNANT PLEURAL MESOTHELIOMA. International Journal of Oncology, 1995, 6, 1261-5.	1.4	0
187	Evaluation of Ki-67 expression as a prognostic feature in hepatocellular carcinoma in cirrhosis. European Journal of Cancer, 1995, 31, 1547-1548.	1.3	5
188	Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. Journal of the American College of Cardiology, 1995, 26, 380-387.	1.2	152
189	FEASIBILITY AND TOLERANCE OF CISPLATIN AND FLUOROURACIL INFUSION IN ELDERLY PATIENTS WITH SQUAMOUS-CELL CARCINOMA. Oncology Reports, 1995, 2, 801-3.	1.2	0
190	Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. European Journal of Cancer, 1994, 30, 430-437.	1.3	120
191	Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. European Heart Journal, 1994, 15, 1089-1095.	1.0	54
192	A Digital Network for Long-distance Echocardiographic Image and Data Transmission in Clinical Trials: The CEDIM Study Experience. Journal of the American Society of Echocardiography, 1993, 6, 583-592.	1.2	11
193	Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: The experience of the National Cancer Institute of Milan. Annals of Oncology, 1993, 4, 489-493.	0.6	15
194	Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma.. Journal of Clinical Oncology, 1993, 11, 1770-1779.	0.8	63
195	Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for Neuroblastoma.. Journal of Clinical Oncology, 1992, 10, 1870-1878.	0.8	31
196	Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Cancer, 1992, 70, 1625-1633.	2.0	97
197	Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases.. Journal of Clinical Oncology, 1991, 9, 962-969.	0.8	60
198	Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. Journal of Antimicrobial Chemotherapy, 1991, 27, 113-120.	1.3	35